In the last trading session, 1.0 million shares of the Stoke Therapeutics Inc (NASDAQ:STOK) were traded, and its beta was 0.93. Most recently the company’s share price was $10.27, and it changed around -$1.08 or -9.52% from the last close, which brings the market valuation of the company to $543.98M. STOK currently trades at a discount to its 52-week high of $17.58, offering almost -71.18% off that amount. The share price’s 52-week low was $4.09, which indicates that the current value has risen by an impressive 60.18% since then. We note from Stoke Therapeutics Inc’s average daily trading volume that its 10-day average is 0.78 million shares, with the 3-month average coming to 737.88K.
Stoke Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended STOK as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Stoke Therapeutics Inc is expected to report earnings per share of -0.54 for the current quarter.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Instantly STOK has showed a red trend with a performance of -9.52% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 12.98 on recent trading dayincreased the stock’s daily price by 20.88%. The company’s shares are currently down -6.89% year-to-date, but still down -10.85% over the last five days. On the other hand, Stoke Therapeutics Inc (NASDAQ:STOK) is 14.62% up in the 30-day period. We can see from the shorts that 8.75 million shares have been sold at a short interest cover period of 9.5 day(s).
The consensus price target as assigned by Wall Street analysts is $26.5, which translates to bulls needing to increase their stock price by 61.25% from its current value. Analyst projections state that STOK is forecast to be at a low of $18 and a high of $35.
Stoke Therapeutics Inc (STOK) estimates and forecasts
The year-over-year growth rate is expected to be 98.32%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 4.2M in revenue for the current quarter. 4 analysts expect Stoke Therapeutics Inc to make 2.83M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.8M and 4.22M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 49.89%. Forecasts for the next quarter put sales growth at -32.99%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -44.06%. Stoke Therapeutics Inc earnings are expected to increase by 14.75% in 2025, but the outlook is negative -2.32% per year for the next five years.
STOK Dividends
Stoke Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.67% of Stoke Therapeutics Inc shares, and 107.75% of them are in the hands of institutional investors. The stock currently has a share float of 113.03%. Stoke Therapeutics Inc stock is held by 175.0 institutions, with SKORPIOS TRUST being the largest institutional investor. By 2024-06-30, it held 23.4474% of the shares, which is about 10.84 million shares worth $146.5 million.
BLACKROCK INC., with 11.6963% or 5.41 million shares worth $73.08 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
